FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The company was incorporated in 2018 and is based in Copenhagen, Denmark.
Metrics to compare | FLUO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFLUOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.6x | 1.8x | −0.6x | |
PEG Ratio | −6.39 | −0.04 | 0.00 | |
Price/Book | −166.5x | 1.2x | 2.6x | |
Price / LTM Sales | −856.8x | 2.0x | 3.3x | |
Upside (Analyst Target) | 238.5% | 144.7% | 44.8% | |
Fair Value Upside | Unlock | 9.4% | 5.5% | Unlock |